CORES: An automated method for generating three-dimensional models of protein/ligand complexes

Journal of Medicinal Chemistry

Volumn 47, Issue 19, 2004, Pages 4731-4740

  Hare, Brian J ^a   Walters, W Patrick ^a   Caron, Paul R ^a   Bemis, Guy W ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; LIGAND; PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; AUTOMATION; COMPLEX FORMATION; CONFORMATION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; LIGAND BINDING; MOLECULAR MODEL; MOLECULAR SIZE; PROTEIN DATA BANK; PROTEIN TARGETING; THREE DIMENSIONAL IMAGING; X RAY ANALYSIS;

BINDING SITES; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEINS; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444377864     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0499054     Document Type: Article

References (35)

1. Brooijmans, N.; Kuntz, I. D. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 335-373.
2. Schneider, G.; Böhm, H.-J. Virtual screening and fast automated docking methods. Drug Discovery Today 2002, 7, 64-70.
3. Krumrine, J.; Raubacher, F.; Brooijmans, N.; Kuntz, I. Principles and methods of docking and ligand design. In Structural Bioinformatics; Bourne, P. E., Weissig, H., Eds.; Wiley-Liss, Inc.: Hoboken, NJ, 2003; pp 443-476.
4. Nissink, J. W. M.; Murray, C.; Hartshorn, M.; Verdenk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein-ligand interaction. Proteins 2002, 49, 457-471.
5. Greenbaum, D. C.; Arnold, W. D.; Lu, F.; Hayrapetian, L.; Baruch, A.; Krumrine, J.; Toba, S.; Chehade, K.; Brömme, D.; Kuntz, I. D.; Bogyo, M. Small molecule affinity fingerprinting a tool for enzyme family subclassification, target identification and inhibitor design. Chem. Biol. 2002, 9, 1085-1094.
6. Baker, D.; Sali, A. Protein structure prediction and structural genomics. Science 2001, 294, 93-96.
7. Fiser, A.; Feig, M.; Brooks, C. L., 3rd; Sali, A. Evolution and physics in comparative protein structure modeling. Acc. Chem. Res. 2002, 35, 413-421.
8. Schwede, T.; Kopp, J.; Guex, N.; Peitsch, M. C. SWISS-MODEL: an automated protein homology-modeling server Nucleics Acids Res. 2003, 31, 3381-3385.
9. Eswar, N.; John, B.; Mirkovic, N.; Fiser, A.; Ilyin, V. A.; Pieper, U.; Stuart, A. C.; Marti-Renom, M. A.; Madhusudhan, M. S.; Yerkovich, B.; Sali, A. Tools for comparative protein structure modeling and analysis. Nucleic Acids Res. 2003, 31, 3375-3380.
10. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
11. Drevs, J.; Medinger, M.; Schmidt-Gersbach, C.; Weber, R.; Unger, C. Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets 2003, 4, 113-121.
12. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G. L.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The protein data bank. Nucleic Acids Res. 2000, 28, 235-242.
13. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and P38 kinase. J. Med. Chem. 2000, 43, 133-138.
14. Pearson, W. R.; Lipman, D. J. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 2444-2448.
15. The kinase protein hinge is a segment connecting the two domains that form the ATP binding site. Jnk3 was chosen as the reference structure because it was an early kinase target for structure-based drug design at Vertex.
16. Xie, X.; Gu, Y.; Fox, T.; Coll, J. T.; Fleming, M. A.; Markland, W.; Caron, P. R.; Wilson, K. P.; Su, M. S. Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. Structure 1998, 6, 983-991.
17. McLachlan, A. D. Rapid comparison of protein structures. Acta Crystallogr. 1982, A38, 871-873.
18. Davies, T. G.; Bentley, J.; Arris, C. E.; Boyle, F. T.; Curtin, N. J.; Endicott, J. A.; Gibson, A. E.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Wang, L.; Whitfield, H. J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 2002, 9, 745-749.
19. DeLano, W. L. The PyMOL Molecular Graphics System (2002). http://www.pymol.org.
20. Stamos, J.; Sliwkowski, M. X.; Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002, 277, 4265-4272.
21. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T., Jr.; Harris, P. A.; Hassell, A.; Holmes, W. D.; Hunter, R. N.; Lackey, K. E.; Lovejoy, B.; Luzzio, M. J.; Montana, V.; Rocque, W. J.; Rusnak, D.; Shewchuk, L.; Veal, J. M.; Walker, D. H.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-4358.
22. Murtagh, F. A survey of recent advances in hierarchical clustering algorithms. Comput. J. 1983, 26, 354-359.
23. Murray, C. W.; Auton, T. R.; Eldridge, M. D. Empirical scoring functions. II. The testing of an empirical scoring function for the prediction of ligand-receptor binding affinities and the use of Bayesian regression to improve the quality of the model. J. Comput.-Aided Mol. Des. 1998, 12, 503-519.
24. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
25. Gibson, A. E.; Arris, C. E.; Benely, J.; Boyle, F. T.; Davis, N. J.; Curtin, T. G.; Endicott, J. A.; Golding, B. T.; Grant, S.; Griffin, R. J.; Jewsbury, P.; Johnson, L. N.; Mesguiche, V.; Newell, D. R.; Noble, M. E.; Tucker, J. A.; Whitfield, H. J. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J. Med. Chem. 2002, 45, 3381-3393.
26. Ikuta, M.; Kamata, K.; Fukasawa, K.; Honma, T.; Machida, T.; Hirai, H.; Suzuki-Takahashi, I.; Hayam, T.; Nishimura, S. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein. J. Biol. Chem. 2001, 276, 27548-27554.
27. De Moliner, E.; Brown, N. R.; Johnson, L. N. Alternative binding modes of an inhibitor to two different kinases. Eur. J. Biochem. 2003, 270, 3174-3181.
28. Gray, N. S.; Wodicka, L.; Thunnissen, A. M.; Norman, T. C.; Kwon, S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; LeClerc, S.; Meijer, L.; Kim, S. H.; Lockhart, D. J.; Schultz, P. G. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors. Science 1998, 281, 533-538.
29. Beattie, J. F.; Breault, G. A.; Ellston, R. P. A.; Green, S.; Jewsbury, P. J.; Midgley, C. J.; Naven, R. T.; Minshull, C. A.; Pauptit, R. A.; Tucker, J. A.; Pease, J. E. Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines. Bioorg. Med. Chem. Lett. 2003, 13, 2955-2960.
30. Dreyer, M. K.; Borcherding, D. R.; Dumont, J. A.; Peet, N. P.; Tsay, J. T.; Wright, P. S.; Bitonti, A. J.; Shen, J.; Kim, S.-H. Crystal structure of human cyclin-dependent kinase 2 in complex with adenine-derived inhibitor H717. J. Med. Chem. 2000, 44, 524-530.
31. Nagar, B.; Bornmann, W.; Pellicena, P.; Schindler, T.; Veach, D.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal structures of the kinase domain of C-Abl in complex with the small molecule inhibitors Pd173955 and Imatinib (Sti-571). Cancer Res. 2002, 62, 4236-4243.
32. Hutchko, S. R.; Hamby, J. M.; Boschelli, D. H.; Wu, Z.; Kraker, A. J.; Amar, A. M.; Hartl, B. G.; Shen, C.; Klohs, W. D.; Steinkampf, R. W.; Driscoll, D. L.; Nelson, J. M.; Elliott, W. L.; Roberts, B. J.; Stoner, C. L.; Vincent, P. W.; Dykes, D. J.; Panek, R. L.; Lu, G. H.; Major, T. C.; Dahring, T. K.; Hallak, H.; Bradford, L. A.; Showalter, H. D.; Doherty, A. M. 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8/H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 1998, 41, 3276-3292.
33. Mohammadi, M.; Froum, S.; Hamby, J. M.; Schroder, M. C.; Panek, R. L.; Lu, G. H.; Eliseenkova, A. V.; Green, D.; Schlessinger, J.; Hubbard, S. R. Crystal structure of an angiogenesis inhibitor bound to the Fgf receptor tyrosine kinase domain. EMBO J. 1998, 17, 5896-5904.
34. Bramson, H. N.; Corona, J.; Davis, S. T.; Dickerson, S. H.; Edelstein, M.; Frye, S. V.; Gampe, R. T.; Hassell, A. H.; Shewchuk, L. M.; Kuyper, L. F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (Cdk2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem. 2001, 44, 4339-4358.
35. De Moliner, E. D.; Moro, S.; Sarno, S.; Zagotto, G.; Zanotti, G.; Pinna, LA.; Battistutta, R. Inhibition of protein kinase CK2 by anthraquinone-related compounds. J. Biol. Chem. 2003, 278, 1831-1836.